 BEVERLY HILLS, Calif., April 19, 2021 PRNewswire -- GT Biopharma, Inc. NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager TriKETM protein biologic technology platform, reported financial results for the fourth quarter and year ended December 31, 2020. 